Unknown

Dataset Information

0

Bortezomib for Reduction of Proteinuria in IgA Nephropathy.


ABSTRACT: Introduction:IgA nephropathy is the most common glomerulonephritis in the world. We conducted a pilot trial (NCT01103778) to test the effect of bortezomib in patients with IgA nephropathy and significant proteinuria. Methods:We treated 8 consecutive subjects from July 2011 until March 2016 with 4 doses of bortezomib. All subjects had biopsy-proven IgA nephropathy and proteinuria of greater than 1 g per day. They were given 4 doses of bortezomib i.v. at 1.3 mg/m2 of body surface area per dose. Changes in proteinuria and renal function were followed for 1 year after enrollment. The primary endpoint was full remission defined as proteinuria of less than 300 mg per day. Results:All 8 subjects received and tolerated 4 doses of bortezomib over a 2-week period during enrollment. The median baseline daily proteinuria was 2.46 g (interquartile range: 2.29-3.16 g). At 1-year follow-up, 3 subjects (38%) had achieved the primary endpoint. The 3 subjects who had complete remission had Oxford classification T scores of 0 before enrollment. Of the remaining 5 subjects, 1 was lost to follow-up within 1 month of enrollment and 4 (50%) did not have any response or had progression of disease. Conclusion:Proteasome inhibition by bortezomib may reduce significant proteinuria in select cases of IgA nephropathy. Subjects who responded to bortezomib had Oxford classification T score of 0 and normal renal function.

SUBMITTER: Hartono C 

PROVIDER: S-EPMC6035125 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bortezomib for Reduction of Proteinuria in IgA Nephropathy.

Hartono Choli C   Chung Miriam M   Perlman Alan S AS   Chevalier James M JM   Serur David D   Seshan Surya V SV   Muthukumar Thangamani T  

Kidney international reports 20180311 4


<h4>Introduction</h4>IgA nephropathy is the most common glomerulonephritis in the world. We conducted a pilot trial (NCT01103778) to test the effect of bortezomib in patients with IgA nephropathy and significant proteinuria.<h4>Methods</h4>We treated 8 consecutive subjects from July 2011 until March 2016 with 4 doses of bortezomib. All subjects had biopsy-proven IgA nephropathy and proteinuria of greater than 1 g per day. They were given 4 doses of bortezomib i.v. at 1.3 mg/m<sup>2</sup> of body  ...[more]

Similar Datasets

| S-EPMC6419287 | biostudies-literature
| S-EPMC10509766 | biostudies-literature
| S-EPMC5667876 | biostudies-literature
| S-EPMC8664351 | biostudies-literature
| S-EPMC4945016 | biostudies-literature
| S-EPMC8054888 | biostudies-literature
| S-EPMC5373458 | biostudies-literature
| S-EPMC10014376 | biostudies-literature
| S-EPMC10382307 | biostudies-literature
| S-EPMC9366370 | biostudies-literature